Xin Lang Cai Jing·2025-08-19 01:24Group 1 - The core viewpoint of the news highlights the significant trading activity and financing status of Junshi Biosciences, with a notable 12.05% increase in stock price on August 18, resulting in a transaction volume of 1.45 billion yuan [1] - On August 18, Junshi Biosciences had a financing buy amount of 139 million yuan, with a net financing buy of -6.37 million yuan, indicating a higher level of financing activity compared to the past year [1] - The total financing and securities lending balance for Junshi Biosciences reached 1.218 billion yuan, with the financing balance accounting for 3.35% of the circulating market value, which is above the 80th percentile of the past year [1] Group 2 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs, with 84.18% of its revenue coming from drug sales [2] - For the first quarter of 2025, Junshi Biosciences reported an operating income of 501 million yuan, reflecting a year-on-year growth of 31.46%, while the net profit attributable to shareholders was -235 million yuan, showing a 17.01% increase [2] - As of March 31, 2025, the number of shareholders for Junshi Biosciences was 29,400, with a slight increase of 0.24% compared to the previous period [2] Group 3 - As of March 31, 2025, among the top ten circulating shareholders of Junshi Biosciences, the Huaxia SSE STAR 50 ETF held 30.2534 million shares, a decrease of 5.0506 million shares from the previous period [3] - The E Fund SSE STAR 50 ETF held 21.5833 million shares, down by 869,200 shares compared to the previous period [3] - Hong Kong Central Clearing Limited increased its holdings to 14.9956 million shares, an increase of 1.5278 million shares from the previous period [3]